Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 29, 2012

View Archived Issues

Chugai Pharmaceutical reflects on milestones of 2011

Modified gold nanoparticles display potent anticoagulant activity

Phase II trial assesses safety paclitaxel/everolimus combination in advanced urothelial cancer

New cognition-enhancing serotonin 5-HT6 receptor antagonist discovered at Cephalon

AnaptysBio describes new antibodies targeting IL-17

Merck & Co. patents novel products with potential to prevent herpes zoster

Novel 5-lipoxygenase inhibitors disclosed by Ranbaxy Laboratories

Medexis reports new products with potential to treat cancer

New cyclopropylamine derivatives designed at Oryzon Genomics

Wakunaga and NeuGen Pharma present new agents for neurological disorders

Zalicus compounds show promise as therapies for absence seizures

Selventa enters new collaboration

Alimera Sciences and pSivida provide update on Iluvien

BioDelivery Sciences and FDA agree on BEMA-buprenorphine/naloxone development plan

Proteonomix gives update on UMK-121 study

Bioheart selects site for ANGEL trial

Phase III trials of 6-month anticancer depot begin in Japan

OncoSec initiates treatment in phase II trial in metastatic melanoma

Antisense Therapeutics to form joint venture for development of ATL-1102

Lundbeck acquires remaining rights to ischemic stroke treatment candidate

New RaQualia product set to enter clinical development

FDA revises labeling for statins

Samsung Biologics and Biogen Idec form joint venture

Abbott enters global agreement for novel JAK1 inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...